Lipocine Inc.
LPCNDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
LPCN 1154A
Depression, Postpartum
Oral testosterone undecanoate, LPCN 1021
Male Hypogonadism
LPCN 1021
Hypogonadism, Male
LPCN 1144 Formulation A
Nonalcoholic Steatohepatitis (NASH)
LPCN 1144
NASH - Nonalcoholic Steatohepatitis
LPCN 1148
Liver Cirrhosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LPCN 1154A | Phase 3 | Depression, Postpartum | - | - |
Oral testosterone undecanoate, LPCN 1021 | Phase 3 | Male Hypogonadism | - | - |
LPCN 1021 | Phase 3 | Hypogonadism, Male | - | - |
LPCN 1144 Formulation A | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
LPCN 1144 | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
LPCN 1148 | Phase 2 | Liver Cirrhosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Lipocine Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Lipocine Inc.'s (LPCN) pipeline across Phase 3, Phase 2. Its lead program is LPCN 1154A (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lipocine Inc.'s next FDA catalyst?→
Lipocine Inc.'s (LPCN) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LPCN biotech catalysts?→
Add LPCN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lipocine Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.